A Phase 2 interventional study of Infigratinib in Hypochondroplasia, sponsored by QED Therapeutics, a BridgeBio company. Enrolling by invitation at 24 sites in 10 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by QED Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Mucopolysaccharidosis IV with a site in United States — 16 open to participants now, 18 under way, 1 of them phase 3. Mucopolysaccharidosis IV · United States.
Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, this one is the 8th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 16 of the 17 other live ones, and was the 51st registered.
101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.
Browse Mucopolysaccharidosis IV studies →16 of the 56 studies in Mucopolysaccharidosis IV with a site in United States are open now. Recruiting first, the newest first:
Kiwi Health Inc · Sites in United States
Ages 18+ · Healthy volunteers
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Children's Hospital of Orange County · Sites in United States
Ages 0–99 · Healthy volunteers
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 2–100
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 7 more countries
Ages 30 mo–16 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 4 · Phase 4 3
First in 1998; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 135 is above the median of 61 across 56 interventional studies indexed under Mucopolysaccharidosis IV.
Median enrollment 88 across the 30 interventional studies, 131 across the 25 observational. Of the 36 that completed or were terminated, 10 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under QED Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, a BridgeBio company is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
BridgeBio has 8 studies filed under Mucopolysaccharidosis IV — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucopolysaccharidosis IV with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT04152551Hospital for Special Surgery, New YorkEffects of Bisphosphonates on OI-Related Hearing Loss | 2027-01 |
| NCT05284006Nemours Children's ClinicNon-invasive Functional Assessment and Pathogenesis of Morquio A | 2027-04-30 |
| NCT05031507Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Study of Skeletal Disorders | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Participants Rolling Over from ACCEL 2/3
Exclusion Criteria:
Exclusion Criteria for Participants Rolling Over from ACCEL 2/3
Children who have completed QED-sponsored interventional study with infigratinib
Drug: Infigratinib
Infigratinib to be administered by mouth and initiated at the last dose level received in the ACCEL 2/3 study or at the dose selected to be further evaluated after proof-of-concept is established for Phase 2 portion of ACCEL 2/3.
Incidence of treatment emergent adverse events (TEAE) and serious TEAE
Time frame: 10 years
Changes over time in standing height Z-score in relation to HCH and non-HCH growth charts
Time frame: 10 years
Changes over time in AHV Z-score
Time frame: 10 years
Changes over time in body proportions
Time frame: 10 years
Changes over time in weight Z-score
Time frame: 10 years
Changes overtime in BMI
Time frame: 10 years
Age of puberty onset and time to Tanner stage ≥4
Time frame: 10 years
Changes over time in body composition as assessed by DXA (dual x-ray absorptiometry) scans
Time frame: 10 years
Changes over time in bone morphology/density by x-ray and DXA
Time frame: 10 years
Change in psychomotor function assessed by age-appropriate computerized tests (Detection Test)
Time frame: 10 years
Change in attention assessed by age-appropriate computerized tests (Identification Test)
Time frame: 10 years
Change in visual learning assessed by age-appropriate computerized tests (One Card Learning Test)
Time frame: 10 years
Change in working memory assessed by age-appropriate computerized tests (One Back Test)
Time frame: 10 years
Changes over time in severity of epilepsy measured by frequency and adverse event grading
Time frame: 10 years
Changes in health-related Quality of life [HRQoL] as assessed by Pediatric Quality of Life Inventory (PedsQL)
Time frame: 10 years
Changes in health-related Quality of life [HRQoL] as assessed by Quality of Life in Short Stature Youth questionnaire (QoLISSY)
Time frame: 10 years
Severity of the physical functioning challenges as assessed by Patient/Parent Global Impression of Severity (PGI-S)
Time frame: 10 years
Severity of the physical functioning challenges as assessed by Patient/Parent Global Impression of Change (PGI-C)
Time frame: 10 years
Subject and caregiver evaluation of treatment benefit as assessed by a qualitative interview
Time frame: 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for May 2036, 121 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib
QED Therapeutics, a BridgeBio company →